# INCY catalysts: INCYTE CORP PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/incy/catalysts

> INCYTE CORP (INCY) has 39 upcoming catalysts. The next is the Povofortay (povorcitinib) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | INCYTE CORP |
| Ticker | INCY (Nasdaq) |
| SEC CIK | 879169 |
| SIC | 8731 |
| SEC filings | https://sec-api.dev/companies/incy |

## Cash runway

Cash $3.28B as of 2026-09-30; quarterly burn $675.3M; about 14.6 months of runway at that rate (XBRL company facts, accession 0000879169-26-000066).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 17, 2020 | [Pemazyre (pemigatinib) FDA approval](https://sec-api.dev/pdufa/pemigatinib) | INCY |  | completed, approved | "NDA213736 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200417, review_priority PRIORITY; sponsor_name INCYTE CORP; product PEMAZYRE (PEMIGATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213736%22)) |
| September 21, 2021 | [JAKAFI (ruxolitinib) FDA approval](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA215309 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20210921, review_priority PRIORITY; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22)) |
| September 22, 2021 | [JAKAFI (ruxolitinib) label expansion decision](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA202192 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20210922, review_priority PRIORITY; sponsor_name INCYTE CORP; product JAKAFI (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202192%22)) |
| Jul 2022 | [OPZELURA (opzelura) FDA approval](https://sec-api.dev/pdufa/opzelura) | INCY |  | completed, approved | "In July 2022, we announced that the FDA approved OPZELURA for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm)) |
| July 18, 2022 | [JAKAFI (ruxolitinib) label expansion decision](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA215309 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220718, review_priority PRIORITY; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22)) |
| August 26, 2022 | [Pemazyre (pemigatinib) label expansion decision](https://sec-api.dev/pdufa/pemigatinib) | INCY |  | completed, approved | "NDA213736 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20220826, review_priority PRIORITY; sponsor_name INCYTE CORP; product PEMAZYRE (PEMIGATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213736%22)) |
| Nov 2022 | [JAKAFI (ruxolitinib) trial start](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed | "In November 2022, we initiated two Phase 2 trials evaluating ruxolitinib cream in lichen planus and lichen sclerosus." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm)) |
| Dec 2022 | [Povofortay (povorcitinib) trial start](https://sec-api.dev/pdufa/povorcitinib) | INCY |  | completed | "In December 2022, we initiated two Phase 3 trials (STOP-HS1 and STOP-HS2) in moderate to severe HS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm)) |
| December 19, 2022 | [JAKAFI (ruxolitinib) label expansion decision](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA202192 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20221219, review_priority PRIORITY; sponsor_name INCYTE CORP; product JAKAFI (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202192%22)) |
| Mar 2023 | [JAKAFI (ruxolitinib) complete response letter (CRL)](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, complete response letter | "Also, in March 2023, we received a complete response letter for ruxolitinib extended release tablets, which identified additional requirements for approval." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm)) |
| Mar 2023 | [ZYNYZ (retifanlimab) FDA approval](https://sec-api.dev/pdufa/retifanlimab) | INCY | with metastatic or recurrent locally advanced Merkel cell carcinoma | completed, approved | "In March 2023, we announced that the FDA had approved ZYNYZ (retifanlimab-dlwr) under accelerated approval, for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm)) |
| March 22, 2023 | [Zynyz (retifanlimab-dlwr) FDA approval](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY | To treat metastatic or recurrent locally advanced Merkel cell carcinoma | completed, approved | "Zynyz \| retifanlimab-dlwr \| 3/22/2023 \| To treat metastatic or recurrent locally advanced Merkel cell carcinomaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| Jul 2023 | [Povofortay (povorcitinib) trial start](https://sec-api.dev/pdufa/povorcitinib) | INCY | moderate to severe uncontrolled asthma | completed | "In July 2023, we initiated a Phase 2 study evaluating povorcitinib in patients with moderate to severe uncontrolled asthma." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm)) |
| Jul 2023 | [Bispecific trial start](https://sec-api.dev/pdufa/bispecific) | INCY | select advanced solid tumors | completed | "In July 2023, we initiated a Phase 1 study evaluating INCA33890 in patients with select advanced/metastatic solid tumors." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm)) |
| Dec 2023 | [JAKAFI (ruxolitinib) complete response letter (CRL)](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, complete response letter | "In December 2023, we received FDA feedback and agreed on the requirements to address the CRL." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm)) |
| Jan 2024 | [JAKAFI (ruxolitinib) topline data readout](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, positive | "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in hidradenitis suppurativa ("HS")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm)) |
| Jul 2024 | [ZYNYZ (retifanlimab) topline data readout](https://sec-api.dev/pdufa/retifanlimab) | INCY |  | completed, positive | "In July 2024, we announced positive topline results from both the two Phase 3 clinical studies evaluating retifanlimab, a humanized monoclonal antibody targeting programmed cell death receptor-1 (PD-1), in SCAC and NSCLC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm)) |
| August 14, 2024 | [Niktimvo (axatilimab-csfr) FDA approval](https://sec-api.dev/pdufa/axatilimab-csfr) | INCY | To treat chronic graft-versus-host disease (cGVHD) | completed, approved | "Niktimvo \| axatilimab-csfr \| 8/14/2024 \| To treat chronic graft-versus-host disease (cGVHD)Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| Oct 2024 | [JAKAFI (ruxolitinib) NDA/BLA submission](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed | "•In October 2024, the sNDA submission for ruxolitinib cream (Opzelura®) in pediatric atopic dermatitis was filed with the FDA with approval anticipated in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm)) |
| Dec 2024 | [MINJUVI (tafasitamab) NDA/BLA submission](https://sec-api.dev/pdufa/tafasitamab) | INCY |  | completed | "In December 2024, we submitted a supplemental Biologics License Application (sBLA) for tafasitamab in relapsed or refractory follicular lymphoma (FL) to the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm)) |
| Jan 2025 | [NIKTIMVO (axatilimab) FDA approval](https://sec-api.dev/pdufa/axatilimab) | INCY |  | completed, approved | "•In January 2025, Incyte and Syndax Pharmaceuticals announced that the FDA approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm)) |
| 2025 | [JAKAFI (ruxolitinib) trial start](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | scheduled | "Incyte plans to initiate a Phase 3 monotherapy study in the post Jakafi patient population in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm)) |
| 2025 | [INCB123667 trial start](https://sec-api.dev/pdufa/incb123667) | INCY |  | scheduled | "▪Incyte plans to initiate Phase 3 studies for its potentially first-in-class CDK2 inhibitor (INCB123667), in ovarian cancer in 2025 and is also evaluating INCB123667 in combination with other treatments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| February 10, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports 2024 Fourth Quarter and Year-End Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm)) |
| Apr 2025 | [JAKAFI (ruxolitinib) topline data readout](https://sec-api.dev/pdufa/ruxolitinib) | INCY | moderate atopic dermatitis | completed, positive | "▪In April 2025, Incyte announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate atopic dermatitis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| Apr 2025 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | chronic spontaneous urticaria | completed, positive | "In April 2025, we announced positive topline results from the Phase 2 study evaluating povorcitinib in patients with CSU." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm)) |
| April 29, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/incy-q12025xexx991.htm)) |
| May 15, 2025 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250515, review_priority PRIORITY; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| May 21, 2025 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Atopic Dermatitis | completed | "NCT06238817 (A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06238817)) |
| Jun 2025 | [MONJUVI (monjuvi) FDA approval](https://sec-api.dev/pdufa/monjuvi) | INCY |  | completed, approved | "▪In June 2025, Monjuvi was approved by the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) in combination with rituximab and lenalidomide." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| Jul 2025 | [JAKAFI (ruxolitinib) topline data readout](https://sec-api.dev/pdufa/ruxolitinib) | INCY | moderate atopic dermatitis | completed, positive | "In July 2025, we announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate AD." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm)) |
| July 7, 2025 | [Pemazyre (pemigatinib) primary completion](https://sec-api.dev/pdufa/pemigatinib) | INCY | Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma | withdrawn | "NCT03656536 (A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-08-11." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03656536)) |
| July 29, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| September 18, 2025 | [JAKAFI (ruxolitinib) label expansion decision](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA215309 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250918, review_priority STANDARD; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22)) |
| September 19, 2025 | [JAKAFI (ruxolitinib) PDUFA date](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "The Prescription Drug User Fee Act (PDUFA) action date was extended by three months to September 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| October 28, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/incy-q32025xexx991.htm)) |
| December 17, 2025 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251217, review_priority STANDARD; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| 1H 2026 | [MINJUVI (tafasitamab) NDA/BLA submission](https://sec-api.dev/pdufa/tafasitamab) | INCY |  | scheduled | "The Company plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line DLBCL in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm)) |
| Q1 2026 | [INCB161734 trial start](https://sec-api.dev/pdufa/incb161734) | INCY |  | scheduled | "Based on the results, the initiation of a Phase 3 study evaluating INCB161734 in first-line patients with metastatic PDAC in combination with chemotherapy versus chemotherapy alone is anticipated in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm)) |
| early 2026 | [Povofortay (povorcitinib) NDA/BLA submission](https://sec-api.dev/pdufa/povorcitinib) | INCY |  | scheduled | "the potential blockbuster opportunity presented by povorcitinib and plans to develop same, including the submission of an NDA in early 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| Q1 2026 | [Povofortay (povorcitinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/povorcitinib) | INCY |  | scheduled | "The acceptance by the FDA of our New Drug Application (NDA) submission for povorcitinib in HS is anticipated in the first quarter of 2026, with potential approval by early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm)) |
| Jan 2026 | [MINJUVI (tafasitamab) topline data readout](https://sec-api.dev/pdufa/tafasitamab) | INCY | newly diagnosed diffuse large B-cell lymphoma | completed, positive | "•In January 2026, the Company announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP as a first-line treatment for adult patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm)) |
| February 10, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm)) |
| February 24, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | NonSegmental Vitiligo | completed | "NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06113445)) |
| February 27, 2026 | [ZYNYZ (retifanlimab) complete response letter (CRL)](https://sec-api.dev/pdufa/retifanlimab) | INCY |  | completed, complete response letter | "On February 27, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the supplemental Biologics License Application ("sBLA") for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") in combination with platinum-based chemotherapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/incy-20260227.htm)) |
| March 3, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Leukemia | completed | "NCT02723994 (A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-03 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02723994)) |
| March 17, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | NonSegmental Vitiligo | completed | "NCT06113471 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06113471)) |
| March 30, 2026 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma | completed | "NCT05429268 (Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05429268)) |
| March 30, 2026 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20260330, review_priority STANDARD; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| April 28, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-q12026xexx991.htm)) |
| May 1, 2026 | [JAKAFI (ruxolitinib) FDA approval](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA217180 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260501, review_priority STANDARD; sponsor_name INCYTE CORP; product JAKAFI XR (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217180%22)) |
| May 11, 2026 | [Itacitinib primary completion](https://sec-api.dev/pdufa/itacitinib) | INCY |  | withdrawn | "NCT04640025 (A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640025)) |
| May 18, 2026 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260518, review_priority STANDARD; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| May 22, 2026 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Atopic Dermatitis | completed | "NCT06238817 (A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06238817?tab=results)) |
| May 29, 2026 | [Pemazyre (pemigatinib) primary completion](https://sec-api.dev/pdufa/pemigatinib) | INCY | Endometrial Cancer | completed | "NCT04463771 (Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04463771)) |
| 2H 2026 | [INCB123667 trial start](https://sec-api.dev/pdufa/incb123667) | INCY |  | scheduled | "The initiation of a Phase 3 study evaluating INCB123667 in first-line maintenance ovarian cancer is anticipated in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm)) |
| 2H 2026 | [INCA033989 trial start](https://sec-api.dev/pdufa/inca033989) | INCY |  | scheduled | "The planned initiation of a Phase 3 trial evaluating INCA033989 in MF is anticipated in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm)) |
| July 28, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm)) |
| August 7, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Atopic Dermatitis | completed | "NCT06832618 (A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-07 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06832618)) |
| September 2026 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Diffuse Large B-cell Lymphoma | delayed | "NCT04824092 (Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04824092)) |
| Sep to Dec 2026 | [MINJUVI (tafasitamab) topline data readout](https://sec-api.dev/pdufa/tafasitamab) | INCY | Diffuse Large B-cell Lymphoma | scheduled | "NCT04824092 (Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04824092)) |
| September 28, 2026 | [INCB099280 primary completion](https://sec-api.dev/pdufa/incb099280) | INCY | Cutaneous Squamous Cell Carcinoma | withdrawn | "NCT05888844 (A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05888844)) |
| September 28, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | completed | "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516965)) |
| Sep to Dec 2026 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | scheduled | "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516965)) |
| September 30, 2026 | [INCB099280 primary completion](https://sec-api.dev/pdufa/incb099280) | INCY | Advanced Solid Tumor | withdrawn | "NCT05879822 (A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-30 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05879822)) |
| Q4 2026 | [JAKAFI (ruxolitinib) topline data readout](https://sec-api.dev/pdufa/ruxolitinib) | INCY | mild to moderate hidradenitis suppurativa | scheduled | "•Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm)) |
| Q4 2026 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | newly diagnosed chronic GVHD | scheduled | "The Company expects to report topline data in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-ex99_1.htm)) |
| October 1, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Chronic Graft-versus-host-disease | completed | "NCT06388564 (A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388564)) |
| Oct 2026 to Jan 2027 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | scheduled | "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516952)) |
| October 1, 2026 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | completed | "NCT06958211 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958211)) |
| Oct 2026 to Jan 2027 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | scheduled | "NCT06958211 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958211)) |
| October 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | delayed | "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516952)) |
| October 29, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm)) |
| October 29, 2026 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | completed | "NCT06959225 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959225)) |
| Oct 2026 to Jan 2027 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | scheduled | "NCT06959225 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959225)) |
| Nov 2026 to Feb 2027 | [Parsaclisib topline data readout](https://sec-api.dev/pdufa/parsaclisib) | INCY | B-Cell Malignancies | scheduled | "NCT04509700 (Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04509700)) |
| Nov 2026 to Feb 2027 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Moderate to Severe Asthma | scheduled | "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05851443)) |
| November 2026 | [Parsaclisib primary completion](https://sec-api.dev/pdufa/parsaclisib) | INCY | B-Cell Malignancies | scheduled | "NCT04509700 (Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04509700)) |
| November 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Moderate to Severe Asthma | scheduled | "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05851443)) |
| Dec 2026 to Mar 2027 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06212999)) |
| December 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06212999)) |
| Apr to Jul 2027 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06804811 (A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804811)) |
| Apr to Jul 2027 | [INCB123667 topline data readout](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07023627 (A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023627)) |
| April 2027 | [INCB123667 primary completion](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07023627 (A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023627)) |
| April 2027 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06804811 (A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804811)) |
| Jul to Oct 2027 | [ATEBRIOZ® (zilurgisertib) topline data readout](https://sec-api.dev/pdufa/zilurgisertib) | INCY | Fibrodysplasia Ossificans Progressiva (FOP) | scheduled | "NCT05090891 (To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05090891)) |
| July 2027 | [ATEBRIOZ® (zilurgisertib) primary completion](https://sec-api.dev/pdufa/zilurgisertib) | INCY | Fibrodysplasia Ossificans Progressiva (FOP) | scheduled | "NCT05090891 (To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05090891)) |
| Aug to Nov 2027 | [MINJUVI (tafasitamab) topline data readout](https://sec-api.dev/pdufa/tafasitamab) | INCY | Hematologic Malignancies | scheduled | "NCT06465433 (Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465433)) |
| August 2027 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Hematologic Malignancies | scheduled | "NCT06465433 (Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465433)) |
| Sep to Dec 2027 | [JAKAFI (ruxolitinib) topline data readout](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer | scheduled | "NCT02955940 (An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02955940)) |
| Sep to Dec 2027 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585774)) |
| Sep to Dec 2027 | [INCA000585 topline data readout](https://sec-api.dev/pdufa/inca000585) | INCY | Immune Thrombocytopenia | scheduled | "NCT07104565 (Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-23 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104565)) |
| September 2027 | [INCA000585 primary completion](https://sec-api.dev/pdufa/inca000585) | INCY | Immune Thrombocytopenia | scheduled | "NCT07104565 (Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-23 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104565)) |
| September 2027 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585774)) |
| September 2027 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer | scheduled | "NCT02955940 (An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02955940)) |
| Feb to May 2028 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855498)) |
| February 2028 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855498)) |
| Mar to Jun 2028 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213973)) |
| March 2028 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213973)) |
| May to Aug 2028 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06821542)) |
| May 2028 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06821542)) |
| Jun to Sep 2028 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06548360 (A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548360)) |
| June 2028 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06548360 (A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548360)) |
| Sep to Dec 2028 | [INCB161734 topline data readout](https://sec-api.dev/pdufa/incb161734) | INCY | Solid Tumors | scheduled | "NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07522073)) |
| September 2028 | [INCB161734 primary completion](https://sec-api.dev/pdufa/incb161734) | INCY | Solid Tumors | scheduled | "NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07522073)) |
| Nov 2028 to Feb 2029 | [INCB123667 topline data readout](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07214779 (Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07214779)) |
| November 2028 | [INCB123667 primary completion](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07214779 (Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07214779)) |
| Dec 2028 to Mar 2029 | [INCA33890 topline data readout](https://sec-api.dev/pdufa/inca33890) | INCY | CRC (Colorectal Cancer) | scheduled | "NCT07284849 (A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284849)) |
| December 2028 | [INCA33890 primary completion](https://sec-api.dev/pdufa/inca33890) | INCY | CRC (Colorectal Cancer) | scheduled | "NCT07284849 (A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284849)) |
| early 2029 | [Latarcibart topline data readout](https://sec-api.dev/pdufa/latarcibart) | INCY |  | scheduled | "Topline data from the VIVID-6 study are anticipated in early 2029." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm)) |
| 2029 | [Bispecific topline data readout](https://sec-api.dev/pdufa/bispecific) | INCY |  | scheduled | "•A Phase 3 study (NEXERA-303) evaluating INCA33890 in combination with SoC chemotherapy and bevacizumab as a first-line treatment in patients with MSS CRC is ongoing, with topline data anticipated in 2029." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm)) |
| Jan to Apr 2029 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT07124078 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07124078)) |
| January 2029 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT07124078 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07124078)) |
| May to Aug 2029 | [INCA33890 topline data readout](https://sec-api.dev/pdufa/inca33890) | INCY | CRC (Colorectal Cancer) | scheduled | "NCT07823322 (A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-14 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823322)) |
| May 2029 | [INCA33890 primary completion](https://sec-api.dev/pdufa/inca33890) | INCY | CRC (Colorectal Cancer) | scheduled | "NCT07823322 (A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-14 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823322)) |
| Jun to Sep 2029 | [INCA033989 topline data readout](https://sec-api.dev/pdufa/inca033989) | INCY | Essential Thrombocythemia | scheduled | "NCT07623200 (A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07623200)) |
| June 2029 | [INCA033989 primary completion](https://sec-api.dev/pdufa/inca033989) | INCY | Essential Thrombocythemia | scheduled | "NCT07623200 (A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07623200)) |

## Drugs

- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab): idiopathic pulmonary fibrosis, newly diagnosed chronic gvhd, chronic graft-versus-host disease, or cgvhd, Chronic Graft-versus-host-disease
- [Niktimvo (axatilimab-csfr)](https://sec-api.dev/pdufa/axatilimab-csfr): To treat chronic graft-versus-host disease (cGVHD)
- [Bispecific](https://sec-api.dev/pdufa/bispecific): select advanced solid tumors, select advanced/metastatic solid tumors
- [INCA000585](https://sec-api.dev/pdufa/inca000585): Immune Thrombocytopenia
- [INCA033989](https://sec-api.dev/pdufa/inca033989): Essential Thrombocythemia
- [INCA33890](https://sec-api.dev/pdufa/inca33890): CRC (Colorectal Cancer)
- [INCB099280](https://sec-api.dev/pdufa/incb099280): Cutaneous Squamous Cell Carcinoma, Advanced Solid Tumor
- [INCB123667](https://sec-api.dev/pdufa/incb123667): Ovarian Cancer
- [INCB161734](https://sec-api.dev/pdufa/incb161734): metastatic pdac, Solid Tumors
- [Itacitinib](https://sec-api.dev/pdufa/itacitinib): Myelofibrosis
- [Latarcibart](https://sec-api.dev/pdufa/latarcibart): 
- [MONJUVI (monjuvi)](https://sec-api.dev/pdufa/monjuvi): 
- [OPZELURA (opzelura)](https://sec-api.dev/pdufa/opzelura): 
- [Parsaclisib](https://sec-api.dev/pdufa/parsaclisib): B-Cell Malignancies
- [Pemazyre (pemigatinib)](https://sec-api.dev/pdufa/pemigatinib): Endometrial Cancer, Unresectable Cholangiocarcinoma
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib): moderate to severe uncontrolled asthma, moderate to severe uncontrolled asthma and in chronic spontaneous urticaria, asthma, chronic spontaneous urticaria, Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis, Moderate to Severe Asthma
- [ZYNYZ (retifanlimab)](https://sec-api.dev/pdufa/retifanlimab): with metastatic or recurrent locally advanced merkel cell carcinoma
- [Zynyz (retifanlimab-dlwr)](https://sec-api.dev/pdufa/retifanlimab-dlwr): To treat metastatic or recurrent locally advanced Merkel cell carcinoma
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib): moderate atopic dermatitis, mild to moderate hidradenitis suppurativa, moderate ad, Pancreatic Cancer, Chronic Graft-versus-host-disease, Leukemia, Atopic Dermatitis
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream): Hidradenitis Suppurativa, NonSegmental Vitiligo, Atopic Dermatitis
- [MINJUVI (tafasitamab)](https://sec-api.dev/pdufa/tafasitamab): newly diagnosed diffuse large b-cell lymphoma, Large B-Cell Lymphoma, Diffuse Large B-cell Lymphoma, Hematologic Malignancies

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/incy/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INCY catalysts: INCYTE CORP PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/incy/catalysts

```bibtex
@misc{secapidev_companies_incy_catalysts_20261116,
  title        = {INCY catalysts: INCYTE CORP PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/incy/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_incy_catalysts_20261116","title":"INCY catalysts: INCYTE CORP PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/incy/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
